BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 865 filers reported holding BAXTER INTL INC in Q3 2015. The put-call ratio across all filers is 0.26 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $527,826 | -21.5% | 13,986 | -5.2% | 0.19% | -20.8% |
Q2 2023 | $672,340 | +7.9% | 14,757 | -3.9% | 0.24% | +4.4% |
Q1 2023 | $622,890 | -31.9% | 15,357 | -14.4% | 0.23% | -31.7% |
Q4 2022 | $914,517 | -7.3% | 17,942 | -2.1% | 0.33% | -16.6% |
Q3 2022 | $987,000 | -17.1% | 18,322 | -1.2% | 0.40% | -12.0% |
Q2 2022 | $1,191,000 | -19.4% | 18,547 | -2.6% | 0.45% | -5.5% |
Q1 2022 | $1,477,000 | -15.5% | 19,047 | -6.4% | 0.48% | -0.8% |
Q4 2021 | $1,747,000 | +5.9% | 20,347 | -0.7% | 0.48% | -1.4% |
Q3 2021 | $1,649,000 | +10.0% | 20,497 | +10.1% | 0.49% | +11.7% |
Q2 2021 | $1,499,000 | -4.4% | 18,622 | +0.1% | 0.44% | -10.1% |
Q1 2021 | $1,568,000 | +2.0% | 18,597 | -3.0% | 0.49% | -5.4% |
Q4 2020 | $1,538,000 | +849.4% | 19,169 | -4.4% | 0.51% | +742.6% |
Q3 2020 | $162,000 | -90.7% | 20,042 | -1.2% | 0.06% | -91.0% |
Q2 2020 | $1,747,000 | +6.1% | 20,292 | 0.0% | 0.68% | -7.9% |
Q1 2020 | $1,647,000 | -1.6% | 20,292 | +1.4% | 0.74% | +22.4% |
Q4 2019 | $1,674,000 | -5.1% | 20,019 | -0.7% | 0.60% | -11.8% |
Q3 2019 | $1,764,000 | +6.8% | 20,169 | 0.0% | 0.68% | +5.2% |
Q2 2019 | $1,652,000 | -49.6% | 20,169 | -50.0% | 0.65% | -1.8% |
Q1 2019 | $3,280,000 | +147.0% | 40,338 | +100.0% | 0.66% | +9.4% |
Q4 2018 | $1,328,000 | -14.9% | 20,169 | -0.4% | 0.60% | +2.2% |
Q3 2018 | $1,560,000 | +1.9% | 20,240 | -2.4% | 0.59% | -6.6% |
Q2 2018 | $1,531,000 | +12.7% | 20,740 | -0.7% | 0.63% | +11.6% |
Q1 2018 | $1,359,000 | -99.9% | 20,890 | -50.7% | 0.57% | +0.5% |
Q4 2017 | $1,371,098,000 | +102990.1% | 42,380 | +100.0% | 0.56% | -4.6% |
Q3 2017 | $1,330,000 | +2.2% | 21,190 | -1.4% | 0.59% | -4.2% |
Q2 2017 | $1,301,000 | +16.0% | 21,490 | -0.7% | 0.62% | +12.2% |
Q1 2017 | $1,122,000 | +16.9% | 21,640 | 0.0% | 0.55% | +10.4% |
Q4 2016 | $960,000 | -7.4% | 21,640 | -0.7% | 0.50% | -13.5% |
Q3 2016 | $1,037,000 | +4.5% | 21,783 | -0.7% | 0.58% | +0.3% |
Q2 2016 | $992,000 | +10.1% | 21,933 | 0.0% | 0.58% | +3.2% |
Q1 2016 | $901,000 | +7.6% | 21,933 | 0.0% | 0.56% | +3.9% |
Q4 2015 | $837,000 | +15.3% | 21,933 | -0.8% | 0.54% | +6.8% |
Q3 2015 | $726,000 | -53.7% | 22,106 | -1.3% | 0.50% | -49.7% |
Q2 2015 | $1,567,000 | +1.4% | 22,406 | -0.7% | 1.00% | +1.6% |
Q1 2015 | $1,545,000 | -6.5% | 22,556 | 0.0% | 0.98% | -8.1% |
Q4 2014 | $1,653,000 | +2.1% | 22,556 | 0.0% | 1.07% | -2.9% |
Q3 2014 | $1,619,000 | -2.2% | 22,556 | -1.5% | 1.10% | -3.8% |
Q2 2014 | $1,655,000 | -1.7% | 22,891 | 0.0% | 1.15% | -6.3% |
Q1 2014 | $1,684,000 | – | 22,891 | – | 1.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |